Balance Sheet (Annual)

USCS / USCorp. Balance Sheet shows account balances for the company at points in time. Balance Sheet data includes Assets, Current Assets, Fixed Assets, Property, Plant and Equipment (PPE), Inventory, Intangibles, Liabilities, Current Liabilities, Debt, Capital Lease Obligations, Common Stock, Retained Earnings, Treasury Stock, and Shareholders Equity.

All numbers are times 1,000 except per share units.

2011 2012 2013 2014 2015 2016 2017
Assets
  Assets Current
    Cash And Cash Equivalents At Carrying Value 341,228 597,461 776,403 971,895 945,605 1,227,862 566,075
    Accounts Receivable Net Current 1,120,246 1,222,345 1,360,443 1,276,224 1,319,558 1,197,678 1,422,101
    Inventory Net 1,453,645 1,354,158 1,399,062 1,482,804 1,611,994 1,569,325 1,705,171
    Other Assets Current 166,108 135,104 177,753 300,646 285,979 298,233 296,712
    Assets Of Disposal Group Including Discontinued Operation Current - - - - - 0 402,065
    Assets Current 3,187,944 3,449,583 3,882,982 4,185,854 4,163,136 4,293,098 4,392,124
  Property Plant And Equipment Net 737,451 828,218 932,792 942,181 988,159 939,650 1,002,700
  Intangible Assets Net Excluding Goodwill 2,958,463 2,917,058 2,960,201 2,433,552 2,112,619 1,839,698 2,089,781
  Goodwill 2,023,460 2,009,757 2,021,750 1,824,956 1,788,407 1,736,959 1,692,644
  Other Assets Noncurrent 405,808 428,405 517,718 593,597 587,221 929,882 781,253
  Disposal Group Including Discontinued Operation Other Noncurrent Assets - - - - - 0 0
  Assets 9,313,126 9,633,021 10,315,440 9,980,140 9,639,542 9,739,287 9,958,502
Liabilities And Stockholders Equity
  Liabilities Current
    Short Term Borrowings 281,686 12,559 18,810 21,822 449,590 26,029 729,384
    Long Term Debt And Capital Lease Obligations Current 2,744 402,873 5,167 3,975 13,279 253,689 6,165
    Accounts Payable Current 637,116 562,638 638,732 690,842 689,594 664,644 755,569
    Accrued Liabilities Current 744,486 754,142 905,292 903,602 789,250 841,038 1,143,330
    Liabilities Of Disposal Group Including Discontinued Operation Current - - - - - 0 110,752
    Liabilities Current 1,666,032 1,732,212 1,568,001 1,620,241 1,941,713 1,785,400 2,745,200
  Long Term Debt And Capital Lease Obligations 1,831,781 1,429,166 1,426,829 1,423,581 1,401,820 2,039,180 2,187,789
  Other Liabilities Noncurrent 1,290,138 1,346,018 1,243,575 1,305,436 911,171 973,786 1,305,613
  Liabilities Of Disposal Group Including Discontinued Operation Noncurrent - - - - - 0 0
  Commitments And Contingencies - - - - - - -
  Liabilities - - - - 4,254,704 4,798,366 6,238,602
  Stockholders Equity
    Preferred Stock Value - - - - 0 0 0
    Common Stock Value 110,557 110,205 110,078 108,215 106,654 103,503 98,955
    Additional Paid In Capital Common Stock 2,316,107 - - - 3,192,675 3,333,423 3,523,340
    Accumulated Other Comprehensive Income Loss Net Of Tax -421,477 -453,895 -211,720 -702,272 -1,043,222 -1,041,463 -926,140
    Retained Earnings Accumulated Deficit 2,520,804 2,941,447 3,432,090 3,231,753 3,128,731 2,545,458 1,023,745
    Stockholders Equity 4,525,991 5,125,625 - - 5,384,838 4,940,921 3,719,900
  Liabilities And Stockholders Equity 9,313,126 9,633,021 10,315,440 9,980,140 9,639,542 9,739,287 9,958,502

Peers - Men's And Boys' Furnishings, Work Clothing, And Allied Garments (232)

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...